XGN Key Statistics, Chart & Performance
The current stock price of XGN is 6.04 USD. In the past month the price decreased by -17.03%. In the past year, price increased by 68.72%.
XGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About XGN
Company Profile
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 203 full-time employees. The company went IPO on 2019-09-19. The firm is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Company Info
EXAGEN INC
1261 Liberty Way
Vista CALIFORNIA 92081 US
CEO: Fortunato Ron Rocca
Employees: 203
Phone: 17605601501
EXAGEN INC / XGN FAQ
Can you describe the business of EXAGEN INC?
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 203 full-time employees. The company went IPO on 2019-09-19. The firm is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
What is the current price of XGN stock?
The current stock price of XGN is 6.04 USD. The price decreased by -0.66% in the last trading session.
Does EXAGEN INC pay dividends?
XGN does not pay a dividend.
How is the ChartMill rating for EXAGEN INC?
XGN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is XGN stock listed?
XGN stock is listed on the Nasdaq exchange.
What is the analyst forecast for XGN stock?
12 analysts have analysed XGN and the average price target is 15.74 USD. This implies a price increase of 160.55% is expected in the next year compared to the current price of 6.04.
When does EXAGEN INC (XGN) report earnings?
EXAGEN INC (XGN) will report earnings on 2026-03-09, after the market close.
XGN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to XGN. When comparing the yearly performance of all stocks, XGN is one of the better performing stocks in the market, outperforming 76.5% of all stocks.
XGN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XGN. XGN has a bad profitability rating. Also its financial health evaluation is rather negative.
XGN Financial Highlights
Over the last trailing twelve months XGN reported a non-GAAP Earnings per Share(EPS) of -0.89. The EPS increased by 5.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.31% | ||
| ROE | -104.97% | ||
| Debt/Equity | 1.35 |
XGN Forecast & Estimates
12 analysts have analysed XGN and the average price target is 15.74 USD. This implies a price increase of 160.55% is expected in the next year compared to the current price of 6.04.
For the next year, analysts expect an EPS growth of -5.72% and a revenue growth 20.35% for XGN